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Coronavirus disease (COVID-19) has shaken the entire 
world from November 2019 affecting over 184 million 
patients infected and 3.96 million deaths worldwide 
as  of  2nd July, 2021. No  proven  therapy exists except  
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for remdesivir that is approved only for patients 
requiring hospitalization.[1] Use of complementary and 
alternative medicine (CAM) in the form of Chinese 
medicine, Ayurveda, Yoga, Unani, Siddha, and 
Homeopathy (AYUSH) have been explored for their 
usefulness in managing COVID-19 patients.[2] Close to 
two-thirds of Indian patients were observed to use 
one of the CAM for treating their disease mainly due 
to the fear of adverse drug reactions due to allopathic 
drugs.[3] This fraction is significantly more with cancer 
patients where the treatment is often sub-optimum 
and cure is uncertain.[4] A study from 495 COVID-19 
patients from an isolation center in India revealed 
that 128 (25.8%) patients used 161 CAM products and 
home remedies where more than half of them used 
Ayurvedic medicine during the treatment and 
following discharge from the hospital.[5] Given the 
A B S T R A C T  
Background: At the backdrop of absence of any approved treatment for COVID-19 infections, Ayurvedic 
treatment can be explored for its potential. AyurCoro-3 is a combination of Gomutra (bos indicus urine), hot water, 
turmeric, Turati churna (potassium Alum), candy sugar (khadisakhar), Bos indicus milk with two teaspoons of Go 
Ghrut (Ghee) with antimicrobial and immunomodulatory properties. The present study evaluated the responses 
from individuals who consumed Ayurcoro-3. Methods: A retrospective observational study was carried out based 
on the participants who consumed Ayurcoro-3. Participants were asked about their reasons for taking the drug, 
whether as prophylaxis/treatment, duration of symptoms following the drug intake compared to baseline, their 
satisfaction with Ayurcoro-3, and adverse events. Results: Two thousand participants were recruited, and majority 
consumed Ayurcoro-3 as a prophylactic drug (1285, 64.25 %). Amongst those who were symptomatic, 317 had 
cough and 328 had fever, and 299 had positive RT-PCR test. The mean (SD) duration of symptoms were 
significantly shorter following the intake of Aurcoro-3 as follows: cough [before: 4.64 (3.26), after: 2.26 (1.34) 
days; p < 0.05], fever [before: 4.16(2.40), after: 2.15(1.34) days; p < 0.05], breathlessness [before: 5.56 (2.66), 
after: 2.30 (1.19) days; p < 0.05], and weakness [before: 5.69 (3.08), after: 2.36 (1.13) days; p < 0.05]. 
Majority of the participants stated that they were very satisfied with Ayurcoro-3. None of the participants reported 
any serious adverse reaction and only few adverse events were reported. Conclusion: We found that Ayurcoro-3 
to be highly effective and safe in preventing/treating COVID-19 related symptoms and the patients are highly 
satisfied with the response. 
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intensity and the risk of infections with mutant 
viruses, and the shortage of allopathic medicines in 
catering to the needs of millions of patients, a cheap 
and easily prepared alternative (a CAM product) is 
preferred. We prepared an Ayurvedic combination 
medicine ‘Ayurcoro-3’ that consisted of Bos Indicus 
distilled urine (BIDU), potassium alum (PA), rock 
candy (RC), Bos Indicus ghee (BIG) and Bos Indicus 
Milk (BIM). The ingredients in this combination have 
been proven to possess anti-microbial, antipyretic, 
and immune boosting properties.[6-8] Ayrucoro-3 is 
dispensed through pharmacy stores as well as 
patients can order it in the product website.[9] We 
carried out the present study to evaluate the efficacy 
and safety of Ayurcoro-3 in preventing COVID-19 
infections amongst the consumers. 
METHODS 
Study ethics and study design 
The study was initiated after obtaining approval from 
the Institutional Ethics committee for biomedical 
research (EC/NEW/INST/2019/245) between January 
and May 2021. The present study was carried out in 
the Bhakti Vedanta Hospital and Research Institute, 
Mumbai, India. Verbal consent was obtained from 
each study participant. We complied with the latest 
Declaration of Helsinki guidelines. 
Study participants 
Ayurcoro-3 is sold from our product website and the 
details of the patients who have ordered the 
medicinal product is retained by the Ayurveda 
Department in the Institute. We retrieved this data 
and contacted the patients who have consumed 
Ayurcoro-3 either for the purpose of prevention or 
treatment of COVID-19 infections.  
Intervention 
The Food and Drug Administration has licensed the 
ingredients of Ayurcoro-3 as drug with 
immunomodulatory properties. AyurCoro-3 medicine 
consists of the following with the instructions 
provided to the consumers: 
▪ Bos indicus urine/hot water/turmeric to be 
gargled twice a day. First gargle one hour prior to 
lunch around 12 noon and second gargle around 9 
PM. 
▪ Turati Churna (potassium Alum) with candy sugar 
(Khadisakhar) in half a glass of warm water mixed 
with bos indicus urine 10 ml, orally. The first dose 
of this intervention should be initiated one hour 
post lunch, the second dose after two hours post 
first dose, and the third dose after two hours 
following the second dose. 
▪ One glass (200 ml) of pure Bos indicus milk with 
two teaspoons of Go Ghrut (Ghee) to be 
administered after one hour of the third dose. 
Study procedure 
We contacted the individuals who have ordered 
Ayurcoro-3 from the product website. The following 
details were obtained from each study participant: 
reason for purchasing Ayurcoro-3 (for the purpose of 
preventing COVID-19 infection with/without exposure 
to COVID-19 positive patients/ or for treatment 
purpose as the individual experienced flu-like 
symptoms such as cough, fever, running nose, and 
myalgia); duration of exposure/symptomatic period 
and dates of consumption of Ayurcoro-3.; date and 
result of investigations pertaining to COVID-19 
infections such as real time-polymerase chain reaction 
(RT-PCR) test, computed tomography test; and 
presence of any co-morbid diseases such as diabetes, 
systemic hypertension, chronic kidney disease, 
bronchial asthma/chronic obstructive pulmonary 
airway disorder; and any side effects following the 
consumption of Ayurcoro-3 medicine.  
A pre-validated six-item scale was used for evaluating 
the satisfaction of the Ayurcoro-3 consumers. The 
face validity of the questionnaire was confirmed by 
the expert panel that constituted experts from the 
Ayurvedic medicine and statistician. The internal 
validity of the scale was confirmed in 30 participants 
and the reliability was evaluated by re-administering 
the same scale in this subset of the study population 
after 7 days. The responses from this subset of 
patients were excluded from the main analysis.  
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Statistical analysis 
Descriptive statistics was used for representing the 
demographic variables. Kappa statistics was used for 
evaluating the reliability of the questionnaire and a 
high degree of agreement was observed with the 
score of 0.87. As this study was primarily intended to 
evaluate the feedback from the consumers, we did 
not estimate the sample size. Numerical variables 
were tested for their distribution using Kolmogorov-
Smirnov test and accordingly Student’s T test was 
used for evaluation of the significance between the 
groups. A p-value of < 0.05 was considered significant.     
RESULTS 
Demographics 
Two-thousand and two-hundred and thirty 
participants were contacted of which 2000 were 
finally recruited. Table 1 summarizes the demographic 
characteristics of the study participants. Majority of 
the study participants were in the middle-aged 
category between 41 and 60 years.  
Response from the study participants 
Majority consumed Ayurcoro-3 as a prophylactic drug 
(1285, 64.25 %). Amongst those who were 
symptomatic, 317 had cough and 328 had fever, and 
299 had positive RT-PCR test. The mean (SD) duration 
of symptoms was significantly shorter following the 
intake of Aurcoro-3 as follows: cough [before: 4.64 
(3.26), after: 2.26 (1.34) days; p < 0.05], fever [before: 
4.16(2.40), after: 2.15(1.34) days; p < 0.05], 
breathlessness [before: 5.56 (2.66), after: 2.30 (1.19) 
days; p < 0.05], and weakness [before: 5.69 (3.08), 
after: 2.36 (1.13) days; p < 0.05]. 
Majority of the participants stated that they were very 
satisfied with Ayurcoro-3 (Figure 1). 
Adverse events 
None of the participants reported any serious adverse 
reaction and only few adverse events were reported 
(Table 2). 
DISCUSSION 
We carried out the present study in 2000 patients 
who took Ayurcoro-3 mainly as a part of preventive 
measure with few with symptoms, and positive for 
COVID-19 infection. Following the intake of Ayurcoro-
3, all the symptoms subsided immediately and almost 
all of them were highly satisfied with the Ayurvedic 
medicine. Only mild adverse events were reported.  
Several Ayurvedic medicines have been shown to be 
useful in ameliorating the signs and symptoms of 
COVID-19 and been debated to be used as vaccines 
[10].  Tulsi/Holy Basil/ Ocimum sanctum, Dalchini / 
Cinnamon / Cinnamomum zeylanicum, Sunthi / Ginger 
/ Zingiber officinale and Marich / Black Pepper / Piper 
nigrum, and Ashwagandha are some other herbal 
medicines that have been explored for their potential 
in curing Covid-19 infections.[11] The modern 
allopathic medicines that have either been proven or 
are under exploration for their therapeutic benefit for 
Covid-19 are expensive, and unavailable due to 
tremendous demand. Considering the fact that more 
than two-thirds of the population in the low- to 
middle-income countries use one of the CAM 
products and that many of such nations have a 
national policy on CAM use, it is imperative that CAM 
products with potential for preventing (by immune 
enhancement) or treating Covid-19 infections have 
more acceptance than the allopathic medicines 
amongst the general population. This is also 
supported by the data on the number of clinical trials 
registered and conducted in India where 61% were 
related to AYUSH interventions.[12] The ingredients 
used in Ayurcoro-3 are easily available and affordable 
and so the chances of demand supply imbalance is 
minimal. Although we did not elicit, we anticipate that 
this could be the most important reason for the high 
satisfaction amongst most of our study participants.  
The strength of this study is that we have elicited the 
response from the end-users of the CAM product. 
Patient-reported outcomes are the crucial and most 
important objective measures that should drive the 
use of new medicinal product rather than based on 
just the clinical/laboratory parameters. However, the 
present study is also limited in not having a control 
group other than baseline duration of symptoms 
amongst those with suspected/confirmed Covid-19 
infections.    
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CONCLUSION 
We observed that our Ayurvedic medicine ‘AyurCoro-
3’ was observed with better satisfaction amongst the 
consumers and was also effective and safe in 
preventing/treating COVID-19 infections.   
FUNDING 
The funder of the study had no role in the study 
design, data collection, data analysis, data 
interpretation or writing of the report. The 
corresponding author had full access to all the data in 
the study and had final responsibility for the decision 
to submit for publication.  
Table 1. Demographic characteristics of the study 
participants (N=2000). 
Parameters Values 
Age (years)α 42.2 (15.1) 
Male β 1256 (62.8) 
Co-existing diseases 
Hypertension β 95 (4.8) 
Ischemic heart disease β 3 (0.2) 
Diabetes β 100 (5) 
Diabetes and systemic hypertension  46 (2.3) 
Presenting symptoms 
Cough β 317 
Breathlessness β 41 
Tastelessness β 13 
Fever β 328 
Weakness  110 
Reason for consuming Ayurcoro-3 
Prophylactic 1285 (64.25) 
Symptomatic 259 (12.95) 
Admitted Patients 291 (14.55) 
Exposed to symptomatic Patients  165 (8.25) 
Patients positivity rate 
RT-PCR 299 (14.95) 
Rapid antigen test 24 (1.2) 
High resolution computed tomography 6 (0.3) 
α – represented in mean (SD); β – represented in n 
(%). 
Table 2. Adverse events reported amongst the study 
participants. 
Event Number of participants reporting 
Nausea 6 
Loss of appetite 5 
Headache 4 
Flatulence 5 
Epigastric pain 1 
Disturbed sleep 3 














Fig.1 Ayurcoro-3 Consumption satisfaction
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